Loading
A phase 3 trial of Rinatabart sesutecan, Paclitaxel / nab-paclitaxel, Topotecan in ovarian cancer, run by Genmab, active and no longer recruiting.
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer is a phase 3 interventional study registered as NCT06619236 by Genmab, with 530 participants planned, started 2025-02-07 and due to reach its primary completion in 2027-02. Interventions recorded: Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Rinatabart sesutecan, Pegylated liposomal doxorubicin, Topotecan, Genmab.
Shares Topotecan, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads), Paclitaxel / nab-paclitaxel.
Shares Rinatabart sesutecan, Genmab, Platinum-resistant ovarian cancer, Topoisomerase-I inhibitors (and ADC payloads).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Pegylated liposomal doxorubicin, Topotecan, Platinum-resistant ovarian cancer, Paclitaxel / nab-paclitaxel.
Shares Pegylated liposomal doxorubicin, Topotecan, Platinum-resistant ovarian cancer, Gemcitabine.
Shares Rinatabart sesutecan, Genmab, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/